Management of pregnancy in women with antithrombin III congenital defect: report of four cases

Thromb Haemost. 1988 Apr 8;59(2):193-6.

Abstract

Four pregnant women with antithrombin III congenital deficiency underwent thrombosis prophylaxis including oral anticoagulants administered from the 16-18th week to the 36-37th week of pregnancy, subcutaneous heparin before the 16-18th week and after the 36-37th week, and a single infusion of AT III concentrate in the peripartum period in order to obtain a minimal level of 0.8 U/ml of AT III functional activity. The level of circulating AT III after the concentrate infusion needs to be evaluated by functional methods, because of a consistent amount in the concentrates of inactive AT III immunoreactive material. No thrombotic or haemorrhagic complication occurred after starting prophylaxis in any woman either in any newborn.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Adult
  • Anticoagulants / administration & dosage
  • Antithrombin III / metabolism
  • Antithrombin III / therapeutic use
  • Antithrombin III Deficiency*
  • Factor Xa
  • Female
  • Heparin / administration & dosage
  • Humans
  • Infant, Newborn
  • Injections, Subcutaneous
  • Male
  • Pregnancy
  • Pregnancy Complications, Hematologic / blood
  • Pregnancy Complications, Hematologic / drug therapy*
  • Serine Proteinase Inhibitors
  • Thromboembolism / prevention & control

Substances

  • Anticoagulants
  • Serine Proteinase Inhibitors
  • Antithrombin III
  • Heparin
  • Factor Xa